[1. Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res. 1998;38(2):291-300.10.1016/S0008-6363(98)00033-9]Open DOISearch in Google Scholar
[2. Vinod NK, Rupinder SM, Murugesan C. Myocardial ischaemic preconditioning. Indian Journal of Anaesthesia. 2004;48:93.]Search in Google Scholar
[3. Duan HF, Wu CT, Wu DL, et al. Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Molecular therapy. 2003;8(3):467-74.10.1016/S1525-0016(03)00186-2]Open DOISearch in Google Scholar
[4. Przyklenk K, Kloner RA. Ischemic preconditioning: exploring the paradox. Progress in cardiovascular diseases. 1998;40:517-47.10.1016/S0033-0620(98)80002-9]Search in Google Scholar
[5. Alserius T, Hammar N, Nordqvist T, Ivert T. Risk of death or acute myocardial infarction 10 years after coronary artery bypass surgery in relation to type of diabetes. Am Heart J. 2006;152(3):599-605.10.1016/j.ahj.2006.02.010]Search in Google Scholar
[6. Cutrn JC, Perrelli MG, Cavalieri B, Peralta C, Rosell Catafau J, Poli J. Microvascular dysfunction induced by reperfusion injury and protective effect of ischemic preconditioning. Free Radic Biol Med. 2002;33(9):1200-8.10.1016/S0891-5849(02)01017-1]Search in Google Scholar
[7. Janoff A. Alterations in lysosomes (intracellular enzymes) during shock; effects of preconditioning (tolerance) and protective drugs. International anesthesiology clinics. 1964;2(2):251-70.10.1097/00004311-196402000-00008]Open DOISearch in Google Scholar
[8. Muller DWM, Topol EJ, Califf RM, Sigmon KN, Gorman L. Relationship between antecedent angina pectoris and short term prognosis after thrombolytic therapy for acute myocardial infarction. Am Heart J. 1990;119:224-31.10.1016/S0002-8703(05)80008-0]Search in Google Scholar
[9. Pomerantz BJ, Joo K, Shames BD, Cleveland JC Jr, Banerjee A, Harken AH. Adenosine preconditioning reduces both pre and postischemic arrhythmias in human myocardium. J Surg Res. 2000;90(2):191-6.10.1006/jsre.2000.588910792962]Open DOISearch in Google Scholar
[10. Luh SP, Yang PC. Organ preconditioning: the past, current status, and related lung studies. J Zhejiang Univ Sci B. 2006;7(5):331-41.10.1631/jzus.2006.B0331146293316615162]Search in Google Scholar
[11. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124-36.10.1161/01.CIR.74.5.11243769170]Search in Google Scholar
[12. Liu Y, Downey JM. Ischemic preconditioning protects against infarction in rat heart. Am J Physiol. 1992;263:H1107-12.10.1152/ajpheart.1992.263.4.H11071415759]Search in Google Scholar
[13. Liu GS, Thornton J, Van Winkle DM, et al. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation. 1991;84:350-6.10.1161/01.CIR.84.1.350]Search in Google Scholar
[14. Schott RJ, Rohmann S, Braun ER, et al. Ischemic preconditioning reduces infarct size in swine myocardium. Circ Res. 1990;66:1133-42.10.1161/01.RES.66.4.11332317890]Search in Google Scholar
[15. Kloner Ra, Shook T, Przyklenk K, et al. Previous angina alters in-hospital outcome in TIMI 4: a clinical correlate to preconditioning? Circulation. 1995;91:37-45.10.1161/01.CIR.91.1.37]Open DOISearch in Google Scholar
[16. Sanada S, Komuro I, Kitakaze M. Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures. Am J Physiol Heart Circ Physiol. 2011;301(5):1723-41.10.1152/ajpheart.00553.201121856909]Search in Google Scholar
[17. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357(11):1121-3510.1056/NEJMra07166717855673]Search in Google Scholar
[18. Iliodromitis EK, Lazou A, Kremastinos DT. Ischemic preconditioning: protection against myocardial necrosis and apoptosis. Vasc Health Risk Manag. 2007;3(5):629-37.]Search in Google Scholar
[19. Speechly-Dick ME, Mocanu MM, Yellon DM. Protein kinase C: its role in ischemic preconditioning in the rat. Circ Res. 1994;75:586-90.10.1161/01.RES.75.3.5868062429]Open DOISearch in Google Scholar
[20. Steenbergen C, Fralix TA, Murphy E. Role of increased cytosolic free calcium concentration in myocardial ischemic injury. Basic Res Cardiol 1993;88:456-70.10.1007/BF007954128117251]Open DOISearch in Google Scholar
[21. Silverman HS, Stern MD. Ionic basis of ischaemic cardiac injury: insights from cellular studies. Cardiovasc Res 1994;28:581-97.10.1093/cvr/28.5.5818025901]Open DOISearch in Google Scholar
[22. Liu Y, Sato T, O’Rourke B, Marban E. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation. 1998;97(24):2463-9.10.1161/01.CIR.97.24.2463]Open DOISearch in Google Scholar
[23. Crossman DC. The pathophysiology of myocardial ischaemia. Heart. 2004;90(5):576-80.10.1136/hrt.2003.029017176824115084567]Open DOISearch in Google Scholar
[24. Jones CJ, Kuo L, Davis MJ, et al. Role of nitric oxide in the coronary microvascular responses to adenosine and increased metabolic demand. Circulation. 1995;91:1807-13.10.1161/01.CIR.91.6.1807]Search in Google Scholar
[25. Meldrum DR. Mechanisms of cardiac preconditioning: ten years after the discovery of ischemic preconditioning. J Surg Res. 1997;73(1):1-13.10.1006/jsre.1997.51879441786]Search in Google Scholar
[26. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013;123(1):92-100.10.1172/JCI62874353327523281415]Search in Google Scholar
[27. Jennings RB, Reimer KA. The cell biology of acute myocardial ischemia. Annu Rev Med. 1991;42:225-46.10.1146/annurev.me.42.020191.0013012035969]Open DOISearch in Google Scholar
[28. Verma S, Fedak PW, Weisel RD, et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation. 2002;105(20):2332-6.10.1161/01.CIR.0000016602.96363.3612021216]Search in Google Scholar
[29. Mittal D, Taliyan R, Sharma PL, Yadav HN. Effect of pioglitazone on the abrogated cardioprotective effect of ischemic preconditioning in hyperlipidemic rat heart. Indian J Pharmacol. 2016;48(1):59-63.10.4103/0253-7613.174545477820926997724]Search in Google Scholar
[30. Dorsch M, Behmenburg F, Raible M, et al. Morphine-Induced Preconditioning: Involvement of Protein Kinase A and Mitochondrial Permeability Transition Pore. PLoS One. 2016;11(3):e0151025.10.1371/journal.pone.0151025478845126968004]Search in Google Scholar
[31. Müllenheim J, Ebel D, Frässdorf J, Preckel B, Thämer V, Schlack W. Isoflurane preconditions myocardium against infarction via release of free radicals. Anesthesiology. 2002;96(4):934–40.10.1097/00000542-200204000-0002211964602]Open DOISearch in Google Scholar
[32. Jeremic N, Petkovic A, Srejovic I, Zivkovic V, Djuric D, Jakovljevic V. Effects of ischemia and omeprazole preconditioning on functional recovery of isolated rat heart. Rev Bras Cir Cardiovasc. 2015;30(2):266-75.10.5935/1678-9741.20150020446297426107460]Search in Google Scholar
[33. Miyawaki H, Ashraf M. Ca2+ as a mediator of ischemic preconditioning. Circ Res. 1997;80: 790-9.10.1161/01.RES.80.6.790]Open DOISearch in Google Scholar
[34. Smith GB, Stefenelli T, Wu ST, Wilkman-Coffelt J, Parmley WW, Zaugg CE. Rapid adaptation of myocardial calcium homeostasis to short episodes of ischemia in isolated rat hearts. Am Heart J. 1996;131:1106-1112.10.1016/S0002-8703(96)90084-8]Search in Google Scholar
[35. Dagenais F, Cartier R, Hollmann C, Buluran J. Calcium-channel blockers preserve coronary endothelial reactivity after ischemia-reperfusion. Ann Thorac Surg. 1997;63:1050-6.10.1016/S0003-4975(96)01278-7]Open DOISearch in Google Scholar
[36. Hugtenburg JG, Van Voorst MJ, Van Marle J, et al. The influence of nifedipine and mioflazine on mitochondrial calcium overload in normoxic and ischaemic guinea-pig hearts. Eur J Pharmacol. 1990;178:71-8.10.1016/0014-2999(90)94794-X]Search in Google Scholar
[37. Braunwald E. Mechanism of action of calcium-channel-blocking agents. New England Journal of Medicine. 1982; 307(26):1618-27.10.1056/NEJM198212233072605]Search in Google Scholar
[38. Brichard G, Zimmermann PE. Verapamil in cardiac dysrhythmias during anesthesia. British Journal of anesthesia. 1970;42(11):1005-12.10.1093/bja/42.11.1005]Search in Google Scholar
[39. Freher M, Challapalli S, Pinto JV, Schwartz J, Bonow RO, Gheorgiade M. Current status of calcium channel blockers in patients with cardiovascular disease. Curr Probl Cardiol. 1999;24:236-40.10.1016/S0146-2806(99)90000-2]Search in Google Scholar
[40. Weir MR. Calcium channel blockers: differences between subclasses. Am J Cardiovasc Drugs. 2007;7:5-15.]Search in Google Scholar
[41. Frishman W.H. Calcium channel blockers: differences between subclasses. Am J Cardiovasc Drugs. 2007;7:17-23.]Search in Google Scholar
[42. Hofmann F, Lacinova L, Klugbauer N. Voltage-dependent calcium channels: From structure to function. Rev Physiol Biochem Pharmacol. 1999;139:33-87.10.1007/BFb0033648]Search in Google Scholar
[43. Cleophas TJ, van Marun R. Meta-analysis of efficacy and safety of second-generation dihydropyridine calcium channel blockers in heart failure. Am J Cardiol. 2001;87:487-90.10.1016/S0002-9149(00)01413-2]Search in Google Scholar
[44. Ruzicka M, Leenen FH. Relevance of 24 H blood pressure profile and sympathetic activity for outcome on short-versus long-acting 1,4-dihydropyridines. Am J Hypertens. 1996;9:86-94.10.1016/0895-7061(95)00350-9]Search in Google Scholar
[45. Millar JA, McLean KA, Sumner DJ, et al. The effect of the calcium antagonist nifedipine on pressor and aldosterone responses to angiotensin II in normal man. Eur J Clin Pharmacol. 1983;24:315-21.10.1007/BF00610047]Open DOISearch in Google Scholar
[46. Krishna GG, Riley LJ, Deuter G, et al. Natriuretic effect of calcium-channel blockers in hypertensives. Am J Kidney Dis. 1991;18:566-72.10.1016/S0272-6386(12)80651-2]Open DOISearch in Google Scholar
[47. Cutler JA. Calcium-channel blocker for hypertension-uncertainty continues. N Engl J Med. 1998; 338:679-81.10.1056/NEJM199803053381009]Search in Google Scholar
[48. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620-5.10.1001/jama.1995.03530080036038]Search in Google Scholar
[49. Shen AC, Jennings RB. Myocardial calcium and magnesium in acute ischemic injury. Am J Pathol. 1972;67(3):417-40.]Search in Google Scholar
[50. Kiowski W, Buhler FR, Fadayomi MO, et al. Age, race, blood pressure and renin: predictors for antihypertensive treatment with calcium antagonists. Am J Cardiol. 1985;56:81-5.10.1016/0002-9149(85)90549-1]Search in Google Scholar
[51. Sica DA. Pharmacotherapy review: calcium channel blockers. J Clin Hypertens (Greenwich). 2006;8(1):53-6.10.1111/j.1524-6175.2005.04140.x810962516407690]Search in Google Scholar
[52. Curt FD, Psaty MB, Meyer VJ. Nifedipine dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-31.10.1161/01.CIR.92.5.13267648682]Search in Google Scholar
[53. Waters D. Proischemic complications of dihydropyridine calcium channel blockers. Circulation. 1991;84:2598-2600.10.1161/01.CIR.84.6.2598]Search in Google Scholar
[54. Cain BS, Meldrum DR, Cleveland JC Jr, Meng X, Banerjee A, Harken AH. Clinical L-type Ca(2+) channel blockade prevents ischemic preconditioning of human myocardium. J Mol Cell Cardiol. 1999;31(12):2191-7.10.1006/jmcc.1999.103910640446]Open DOISearch in Google Scholar
[55. Wallbridge DR, Schulz R, Braun C, Post H, Heusch G. No attenuation of ischaemic preconditioning by the calcium antagonist nisoldipine. J Mol Cell Cardiol. 1996;28(8):1801-10.10.1006/jmcc.1996.01698877789]Search in Google Scholar
[56. Camara AK, Chen Q, Rhodes SS, Riess ML, Stowe DF. Negative inotropic drugs alter indexes of cytosolic [Ca(2+)]-left ventricular pressure relationships afterischemia. Am J Physiol Heart Circ Physiol. 2004;287(2):H667-80.10.1152/ajpheart.01142.2003]Search in Google Scholar
[57. Dilmac N, Hilliard N, Hockerman GH: Molecular determinants of frequency dependence and Ca2+ potentiation of verapamil block in the pore region of Cav1.2. Mol Pharmacol. 2004;66(5):1236-47.10.1124/mol.104.000893]Open DOISearch in Google Scholar
[58. Miyawaki H, Zhou X, Ashraf M. Calcium preconditioning elicits strong protection against ischemic injury via protein kinase C signaling pathway. Circ Res. 1996;79:137-146.10.1161/01.RES.79.1.137]Open DOISearch in Google Scholar
[59. Henry PD. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. The American journal of cardiology. 1980;46(6):1047-58.10.1016/0002-9149(80)90366-5]Search in Google Scholar
[60. Yu W, Wang JJ, Gan WY, Lin GS, Huang CX. Effects of verapamil preconditioning on cardiac function in vitro and intracellular free Ca2+ and L-type calcium current in rat cardiomyocytes post ischemia-reperfusion injury. Zhonghua Xin Xue Guan Bing Za Zhi. 2010;38(3):225-9.]Search in Google Scholar
[61. Okuda K, Nohara R, Ogino M, et al. Limitation of infarct size with preconditioning and calcium antagonist (Diltiazem): Difference in 99mTc-PYP uptake in the myocardium. Annals of nuclear medicine. 1996;10(2):201-9.10.1007/BF03165393]Search in Google Scholar
[62. De Jong JW, Harmsen E, De Tombe PP. Diltiazem administered before or during myocardial ischemia decreases adenine nucleotide catabolism. J Mol Cell Cardiol. 1984;16(4):363-70.10.1016/S0022-2828(84)80607-0]Open DOISearch in Google Scholar
[63. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol. 1989;63:18J-24J.10.1016/0002-9149(89)90200-2]Search in Google Scholar
[64. The IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomized trial. Lancet 2002;359:1269–75.10.1016/S0140-6736(02)08265-X]Search in Google Scholar
[65. Lablanche JM, Bauters C, Leroy F et al. Prevention of coronary spasm by nicorandil: Comparison with nifedipine. J Cardiovasc Pharmacol. 1992;20:S82–5.10.1097/00005344-199206203-00014]Search in Google Scholar
[66. Ohno Y, Minatoguchi S, Uno Y, Kariya T, Arai M, Yamashita K, Fujiwara T, Fujiwara H. Nicorandil reduces myocardial infarct size by opening the K(ATP) channel in rabbits. Int J Cardiol. 1997;62(3):181-90.10.1016/S0167-5273(97)00270-2]Open DOISearch in Google Scholar
[67. Matsubara T, Minatoguchi S, Matsuo H, et al. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease. J Am Coll Cardiol. 2000;35(2):345-51.10.1016/S0735-1097(99)00539-2]Open DOISearch in Google Scholar
[68. Tang XL, Xuan YT, Zhu Y, Shirk G, Bolli R. Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits. Am J Physiol Heart Circ Physiol. 2004;286(4):H1273-80.10.1152/ajpheart.01055.2003]Search in Google Scholar
[69. Ahmed LA, Salem HA, Attia AS, Agha AM. Pharmacological preconditioning with nicorandil and pioglitazone attenuates myocardial ischemia/reperfusion injury in rats. Eur J Pharmacol. 2011;663(1-3):51-8.10.1016/j.ejphar.2011.04.038]Search in Google Scholar
[70. Rajesh KG, Sasaguri S, Zhitian Z, Suzuki R, Asakai R, Maeda H. Second window of ischemic preconditioning regulates mitochondrial permeability transition pore by enhancing Bcl-2 expression. Cardiovasc Res. 2003;59(2):297-307.10.1016/S0008-6363(03)00358-4]Search in Google Scholar
[71. Matsuo H, Watanabe S, Segawa T, et al. Evidence of pharmacologic preconditioning during PTCA by intravenous pretreatment with ATP-sensitive K+ channel opener nicorandil. Eur Heart J. 2003;24(14):1296-303.10.1016/S0195-668X(03)00202-1]Search in Google Scholar
[72. Sakai K, Yamagata T, Teragawa H, Matsuura H, Chayama K. Nicorandil enhances myocardial tolerance to ischemia without progressive collateral recruitment during coronary angioplasty. Circulation journal. 2002;66(4):317-22.10.1253/circj.66.317]Open DOISearch in Google Scholar
[73. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): 2 randomised trials. Lancet. 2007;370(9597):1483-93.10.1016/S0140-6736(07)61634-1]Search in Google Scholar